17 years ago, James Muller, a former medical professor at Harvard Medical School, wanted to develop an intravascular imaging device to promote the diagnosis and management of coronary artery disease. Muller founded Infraredx to bring infrared imaging equipment to market. Since then, the company has gone through thousands of days to bring the US Food and Drug Administration (FDA) officially licensed equipment to the market, withdrawing $56 million in initial public offerings (IPOs). Last week, Infraredx's move to acquire Nipro ushered in another milestone. Jonathan Isenburg, Chief Financial Officer of Infraredx, revealed in Medical Device Daily, "I am very grateful to Dr. Muller for creating the company's dream and its insistence on the conditions of heart disease detection. This is not the end, but a new beginning." He added, "Dr. Muller will continue to participate and seek successful results from clinical trial research systems." The company's PROSPECT II already includes a multicenter, prospective study involving 900 patients involved in the evaluation of intravascular imaging systems. Detected. The financial details of the upcoming acquisition plan have not been disclosed. In the past, the two companies have cooperated. Infraredx and Nipro have a five-year exclusive distribution agreement to sell technology from private companies. It is reported that the upcoming acquisition plan will introduce Nipro's cardiovascular products into the United States. Infraredx will continue to authorize interventional cardiologists to use imaging equipment to predict and prevent heart attacks - promoting coronary artery disease from reactive therapy to active care change. “The Nipro Group has extensive experience in intravascular imaging systems, and it is the knowledge and expertise of its intravascular imaging that led to Infraredx's acquisition of Nipro.†Infraredx's TV Imager (TVC) system already has an official license from the US Food and Drug Administration (FDA) and a European certification (CE mark). The system is based on near-infrared spectroscopy (NIRS) and intravascular ultrasound imaging (IVUS) and was approved in Japan last year. LipiScan's Intravascular Ultrasound Imaging (IVUS) system is designed to provide a patient's grayscale coronary intravascular ultrasound image and a complete serum chemistry map - a picture of the lipid core plaque. The company is collecting additional data from clinical trials to support the use of intravascular imaging systems to predict heart attacks. Nipro Chairman Yoshihiko Sano said, "Infraredx founder James Muller and his management team have given the interventional cardiologist the ability to image near-infrared spectroscopy (NIRS) and intravascular ultrasound imaging (IVUS), allowing detection to cause most Lipid core plaques for heart attacks. Nipro and Infraredx will always adhere to a patient-centric, global portfolio combined with cardiovascular expertise to provide the most comprehensive imaging solution to change the formation of cardiovascular disease. We look forward to both sides Work together to provide the best medicine and innovation." Nipro offers a wide range of products and technologies such as artificial organs, recycling equipment, test/diagnostic formulations, injection/infusion solutions, ethical medicines and medical glass products to meet the needs of patients and medical professionals. The acquisition plan is expected to be completed in October. Nipro's stock opened at $13,160 and closed at $1,340 with a premium of 1.13%. In January, the company drafted a public offering of shares. Infraredx said the company plans to issue 4 million shares between $13 and $15, hoping to grow to 56 million shares. However, in February, the company withdrew the plan because of the “unfavorable market conditions†of the IPO. Isenburg said the company's divestment from the IPO has nothing to do with the upcoming M&A plan. Isenburg said there are many reasons for the company to withdraw from the IPO. However, the purpose of this transaction is to spread our technology and continue to fulfill our mission to explore and fundamentally prevent the onset of heart disease. Vietnam'S Export Products,Sugandha Paddy Seeds,Seed Paddy,Wild Rice Seed XIKE AGRICULTURAL GROUP CO . .LTD. , https://www.laoseed.com